Battery-Powered Skin Patch for PAD treatment

Scientists have confirmed the feasibility of using a new drug delivery system - the basis for a battery-powered skin patch - to administer medication that shows promise for treating peripheral artery disease (PAD) and healing stubborn skin ulcers and burns. The needle-free delivery of the medication, which cannot be given by mouth and can have side effects when injected, is reported in the ACS journal, Molecular Pharmaceutics.

Yogeshvar Kalia and colleagues explain that the medication consists of fibroblast growth factors (FGFs), proteins that have shown promise for treating skin conditions and PAD, which causes pain in the legs, buttocks, and feet due to blocked arteries in the legs. However, FGFs become inactive if given by mouth, and their injection can result in kidney and eye damage. The scientists had previously shown that a drug delivery technology called transdermal iontophoresis can deliver medicines made from small proteins. But would the technique, which involves encouraging medicine through the skin with a small electric current, work for larger proteins like FGFs?

Their laboratory tests with samples of human skin and pig skin showed that iontophoresis did work - in contrast, no FGF was delivered without electricity. Four times more medication remained in the skin than passed through which was also an advantage. Most importantly, the medicine remained biologically active in the skin. The results confirm the feasibility of using iontophoresis to deliver medicines consisting of larger proteins, including FGFs, the scientists note.

 

11.08.2011

More on the subject:

Related articles

Photo

News • Stratification of TSCC immunotypes

Tongue cancer: Immune profiling for improved outcomes

Tongue squamous cell carcinoma, the most common type of oral cancer, is a challenging target for immunotherapies. Researchers now identified five immunotypes to better predict treatment response.

Photo

News • Machine learning analysis

Cancer genomics: new ML tool weeds out false positives

A major challenge in cancer genomics is separating meaningful mutations from false positives. A new tool uses machine learning to significantly reduce these errors.

Photo

News • From same-day to several years

Childhood cancer: stark inequalities in diagnostic waiting times

Childhood cancer diagnosis times span from immediate to delays of several years, according to a new study. Young bone tumor patients are among the most affected by these delays.

Related products

Subscribe to Newsletter